Metacrine, a Phase 1 biotech developing FXR agonist therapies for NASH, raised $85 million by offering 6.5 million shares at $13, within the range of $12 to $14. At pricing, the company commands a fully diluted market value of $364 million.
Metacrine plans to list on the Nasdaq under the symbol MTCR. Jefferies, Evercore ISI and RBC Capital Markets acted as lead managers on the deal.
